文献速递临床试验与 GCP流行病学与生物统计新药、器械与细胞基因治疗研发

抗体与细胞疗法治疗COVID-19:活系统评价与网络meta分析

Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis.
PubMed 文献 · BMJ · 2021-09-23

该活系统评价与网络meta分析评估了抗病毒抗体疗法和血液制品治疗COVID-19的疗效与安全性,检索截至2021年7月21日,纳入47项试验。非重症患者中,抗病毒单克隆抗体(casirivimab-imdevimab等)可能降低住院风险,而恢复期血浆、IVIg等未显示有意义获益。重症患者中除casirivimab-imdevimab可能降低血清阴性者死亡率外,其他干预无重要影响。

要点

  • 非重症COVID-19患者使用casirivimab-imdevimab可能降低住院风险(OR 0.29)。
  • bamlanivimab、bamlanivimab-etesevimab和sotrovimab可能降低非重症患者住院风险。
  • 恢复期血浆、IVIg等抗体及细胞干预对非重症或重症患者可能无有意义获益。

核心结论

  • 非重症COVID-19患者中,casirivimab-imdevimab可能降低住院风险;bamlanivimab-etesevimab、bamlanivimab和sotrovimab可能降低住院风险。
  • 恢复期血浆、IVIg和其他抗体及细胞干预可能不带来任何有意义获益。

研究设计与样本

  • 活系统评价与网络meta分析,数据来源为WHO COVID-19数据库和六个中文数据库(截至2021年7月21日)。
  • 纳入将疑似、可能或确诊COVID-19患者随机分配至抗病毒抗体疗法、血液制品、标准治疗或安慰剂的试验,共47项。

主要发现

  • 非重症患者中,casirivimab-imdevimab降低住院风险(OR 0.29,95%CI 0.17-0.47;RD -4.2%;中等确定性)。
  • bamlanivimab降低住院风险(OR 0.24,95%CI 0.06-0.86;RD -4.1%;低确定性)。
  • bamlanivimab-etesevimab降低住院风险(OR 0.31,95%CI 0.11-0.81;RD -3.8%;低确定性)。
  • sotrovimab降低住院风险(OR 0.17,95%CI 0.04-0.57;RD -4.8%;低确定性)。
  • 重症或危重症患者中,除casirivimab-imdevimab可能降低血清阴性者死亡率外,无干预对任何结局有重要影响。

临床怎么用

  • 非重症COVID-19患者可考虑使用casirivimab-imdevimab以降低住院风险,其他单克隆抗体证据确定性较低。
  • 不推荐常规使用恢复期血浆、IVIg或其他抗体及细胞干预治疗COVID-19,因其可能无有意义获益。

局限性

  • 本系统评价未注册。
  • 部分结局数据不足,仅进行配对meta分析。
  • 证据确定性对于多数单克隆抗体为低,需更新证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of antiviral antibody therapies and blood products for the treatment of novel coronavirus disease 2019 (covid-19). DESIGN: Living systematic review and network meta-analysis, with pairwise meta-analysis for outcomes with insufficient data. DATA SOURCES: WHO covid-19 database, a comprehensive multilingual source of global covid-19 literature, and six Chinese databases (up to 21 July 2021). STUDY SELECTION: Trials randomising people with suspected, probable, or confirmed covid-19 to antiviral antibody therapies, blood products, or standard care or placebo. Paired reviewers determined eligibility of trials independently and in duplicate. METHODS: After duplicate data abstraction, we performed random effects bayesian meta-analysis, including network meta-analysis for outcomes with sufficient data. We assessed risk of bias using a modification of the Cochrane risk of bias 2.0 tool. The certainty of the evidence was assessed using the grading of recommendations assessment, development, and evaluation (GRADE) approach. We meta-analysed interventions with ≥100 patients randomised or ≥20 events per treatment arm. RESULTS: As of 21 July 2021, we identified 47 trials evaluating convalescent plasma (21 trials), intravenous immunoglobulin (IVIg) (5 trials), umbilical cord mesenchymal stem cells (5 trials), bamlanivimab (4 trials), casirivimab-imdevimab (4 trials), bamlanivimab-etesevimab (2 trials), control plasma (2 trials), peripheral blood non-haematopoietic enriched stem cells (2 trials), sotrovimab (1 trial), anti-SARS-CoV-2 IVIg (1 trial), therapeutic plasma exchange (1 trial), XAV-19 polyclonal antibody (1 trial), CT-P59 monoclonal antibody (1 trial) and INM005 polyclonal antibody (1 trial) for the treatment of covid-19. Patients with non-severe disease randomised to antiviral monoclonal antibodies had lower risk of hospitalisation than those who received placebo: casirivimab-imdevimab (odds ratio (OR) 0.29 (95% CI 0.17 to 0.47); risk difference (RD) -4.2%; moderate certainty), bamlanivimab (OR 0.24 (0.06 to 0.86); RD -4.1%; low certainty), bamlanivimab-etesevimab (OR 0.31 (0.11 to 0.81); RD -3.8%; low certainty), and sotrovimab (OR 0.17 (0.04 to 0.57); RD -4.8%; low certainty). They did not have an important impact on any other outcome. There was no notable difference between monoclonal antibodies. No other intervention had any meaningful effect on any outcome in patients with non-severe covid-19. No intervention, including antiviral antibodies, had an important impact on any outcome in patients with severe or critical covid-19, except casirivimab-imdevimab, which may reduce mortality in patients who are seronegative. CONCLUSION: In patients with non-severe covid-19, casirivimab-imdevimab probably reduces hospitalisation; bamlanivimab-etesevimab, bamlanivimab, and sotrovimab may reduce hospitalisation. Convalescent plasma, IVIg, and other antibody and cellular interventions may not confer any meaningful benefit. SYSTEMATIC REVIEW REGISTRATION: This review was not registered. The protocol established a priori is included as a data supplement. FUNDING: This study was supported by the Canadian Institutes of Health Research (grant CIHR- IRSC:0579001321). READERS' NOTE: This article is a living systematic review that will be updated to reflect emerging evidence. Interim updates and additional study data will be posted on our website (www.covid19lnma.com).

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Siemieniuk RA, Bartoszko JJ, Díaz Martinez JP, et al. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. BMJ. 2021. PMID: 34556486. doi:10.1136/bmj.n2231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。